MLICM
KRYS icon

Metropolitan Life Insurance Company (MetLife)’s Krystal Biotech KRYS Stock Holding History

Metropolitan Life Insurance Company (MetLife)’s Portfolio KRYS Stock Details KRYS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-1,136
Closed -$202K – 1142
2024
Q1 		$202K Sell
1,136
-110
-9% -$15.3K 0.01% 715
2023
Q4 		$155K Hold
1,246
– – 0.01% 864
2023
Q3 		$145K Buy
1,246
+76
+6% +$9.27K 0.01% 832
2023
Q2 		$137K Buy
1,170
+43
+4% +$4.39K 0.01% 860
2023
Q1 		$90.2K Sell
1,127
-156
-12% -$12.3K ﹤0.01% 1044
2022
Q4 		$102K Hold
1,283
– – ﹤0.01% 1047
2022
Q3 		$89.4K Hold
1,283
– – ﹤0.01% 1074
2022
Q2 		$84.2K Hold
1,283
– – ﹤0.01% 1168
2022
Q1 		$85.4K Sell
1,283
-3,503
-73% -$219K ﹤0.01% 1294
2021
Q4 		$335K Hold
4,786
– – ﹤0.01% 1678
2021
Q3 		$250K Buy
4,786
+91
+2% +$5.39K ﹤0.01% 1908
2021
Q2 		$319K Buy
4,695
+311
+7% +$21.7K ﹤0.01% 1810
2021
Q1 		$338K Sell
4,384
-238
-5% -$17.3K 0.01% 1675
2020
Q4 		$277K Hold
4,622
– – ﹤0.01% 1723
2020
Q3 		$199K Hold
4,622
– – ﹤0.01% 1779
2020
Q2 		$191K Buy
4,622
+1,360
+42% +$65.4K ﹤0.01% 1824
2020
Q1 		$141K Hold
3,262
– – ﹤0.01% 1807
2019
Q4 		$181K Hold
3,262
– – ﹤0.01% 1992
2019
Q3 		$113K Buy
3,262
+2,551
+359% +$114K ﹤0.01% 2231
2019
Q2 		$28.6K Buy
+711
New +$23.2K ﹤0.01% 2556

Other funds holding KRYS

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

Metropolitan Life Insurance Company (MetLife)'s KRYS Position: Q2 2024 in Review

Metropolitan Life Insurance Company (MetLife) sold out of Krystal Biotech (KRYS) in Q2 2024, closing a stake of 1,136 shares — an estimated $202K sold.

Metropolitan Life Insurance Company (MetLife) first reported a position in KRYS in Q2 2019 and held it in 20 quarters. The position peaked at $338K in Q1 2021. 245 funds tracked by Wall St. Rank hold KRYS as of Q2 2024.

  • Metropolitan Life Insurance Company (MetLife) reported no remaining Krystal Biotech position as of Q2 2024 after selling out during the quarter.
  • Metropolitan Life Insurance Company (MetLife) sold 1,136 Krystal Biotech shares in Q2 2024, an estimated $202K.
  • Metropolitan Life Insurance Company (MetLife) first reported a position in Krystal Biotech in Q2 2019 and held it in 20 quarters.
  • Metropolitan Life Insurance Company (MetLife)'s Krystal Biotech position peaked at $338K in Q1 2021.
  • 245 funds tracked by Wall St. Rank held Krystal Biotech as of Q2 2024.

Based on Metropolitan Life Insurance Company (MetLife)'s 13F filing for Q2 2024, filed 13 Aug 2024.